US Global Jets ETF vs Liquidia Corporation Common Stock — how do they compare? US Global Jets ETF trades at $25.81 (market cap $812.53M), while Liquidia Corporation Common Stock trades at $33.5 (market cap $2.40B). The key difference: Liquidia Corporation Common Stock is far larger — about 3× US Global Jets ETF's market cap, and US Global Jets ETF is more actively traded (5,144,947 versus 2,857,547). Which is the better fit depends on your goals — on Pluang, investors hold US Global Jets ETF for 27 Days and Liquidia Corporation Common Stock for 0 Days on average.
| JETS | LQDA | |
|---|---|---|
Market Cap | $812.53M | $2.40B |
Volume | 5,144,947 | 2,857,547 |
Sector | Sector/Thematic | Health |
52-Week High | $33.53 | $91.03 |
52-Week Low | $23.64 | $22.02 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | — | $2.30B |
Signals from Pluang's Aura AI — not financial advice
JETS is trading at $26.80, down 0.81% with a bearish technical outlook indicated by moving averages. The ETF faces headwinds from rising fuel costs and geopolitical tensions, though strong travel demand provides some support. Recent news highlights underperformance compared to aerospace/defense ETFs, with fuel expenses surging 85% in May 2026 according to Reuters.
The outlook remains cautious due to fuel price volatility and competitive pressure from alternative aviation ETFs. Near-term performance depends on fuel cost management and travel demand sustainability, with technical support at $26 providing a key level to watch.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →